

























SuperGen to Present at BioEquity Europe on May 23rd & 24th
Published in Health and Fitness on Monday, May 16th 2011 at 5:05 GMT by Market Wire

DUBLIN, Calif.--([ BUSINESS WIRE ])--SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at BioEquity Europe 2011 on Monday and Tuesday, May 23rd and 24th in Paris.
SuperGen's corporate presentation will take place on May 23 at 11:00 a.m. CEST. In addition, Dr. Manuso will participate in a panel discussion titled, aStrategy: Squaring the Circlea about building companies to study disease biology based on platform technology, on May 24 at 1:45 p.m. CEST. More information on the panel can be found at [ http://www.biocentury.com/Conferences ].
About SuperGen
SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit [ http://www.supergen.com ].